格隆汇8月12日丨国药控股(01099.HK)公告，将于2025年8月22日(星期五)举行董事会会议，藉以考虑及 批准(其中包括)公司及其附属公司截至2025年6月30日止6个月未经审核中期业绩。 ...

中國，上海 2025 年 8 月 12 日 於本通告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先生、祖敬 先生、邢永剛先生、陳玉卿先生、文德鏞先生及馮蓉麗女士；獨立非執行董事為李培育先生、吳德龍 先生、俞衛鋒先生、石晟昊先生及陳威如先生。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 董事會會議通告 國藥控股股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，將於 2025 年 8 月 22 日（星期五）舉行董事會會議，藉以考慮及批准（其中包括）本公司及其附屬公司截至 2025 年 6 月 30 日止六個月之未經審核中期業績。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 國藥控股股份有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01099 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,341,810,740 | RMB | | | 1 RMB | | 1,341,810,740 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 1,341,810,740 | RMB | | | 1 RMB | | 1,341,810,740 | | 2. 股份分類 ...

Core Viewpoint - The China Securities Index for Hong Kong Stock Connect Medical Theme has shown significant growth, with a year-to-date increase of 58.75% [1] Group 1: Index Performance - The index rose by 2.58% to 1088.62 points, with a trading volume of 19.47 billion [1] - Over the past month, the index has increased by 16.48%, and over the last three months, it has risen by 31.51% [1] Group 2: Index Composition - The index comprises 50 listed companies involved in medical devices, medical services, pharmaceuticals, and biotechnology [1] - The top ten weighted companies in the index include WuXi Biologics (15.03%), JD Health (10.75%), and WuXi AppTec (6.59%) [1] Group 3: Sector Allocation - The index's holdings are entirely from the Hong Kong Stock Exchange [2] - The sector breakdown of the index includes: Pharmaceuticals and Biotechnology Services (33.30%), Medical Services (32.85%), Medical Devices (12.81%), Chemical Drugs (12.34%), and Biological Drugs (8.70%) [2] Group 4: Index Adjustment Mechanism - The index samples are adjusted biannually, with changes implemented on the next trading day after the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special adjustments made under certain circumstances [2]

Group 1 - The core point of the news is the suspension of procurement activities for two subsidiaries of China National Pharmaceutical Group Corporation (Sinopharm) due to violations of procurement regulations [1][7][9] - The companies involved are Sinopharm (Tianjin) Dongfang Bokang Pharmaceutical Co., Ltd. and Sinopharm Medical Technology (Tianjin) Co., Ltd., both of which are accused of engaging in fraudulent bidding practices [1][7] - The suspension will take effect from June 20, 2025, and will prevent the companies and their associated representatives from participating in military procurement activities during the suspension period [2][9] Group 2 - Sinopharm (Tianjin) Dongfang Bokang Pharmaceutical Co., Ltd. was established on January 6, 1994, and its current legal representative is Liu Zhanwen [13][14] - Sinopharm Medical Technology (Tianjin) Co., Ltd. was established on February 22, 2012, and its current legal representative is Kuang Yu [18] - The legal representatives and major shareholders of both companies are prohibited from participating in military procurement activities during the suspension [2][9]

Core Viewpoint - The China Securities Index for Hong Kong Stock Connect Medical Theme Index has shown a recent decline of 0.75%, but it has experienced significant growth over the past months, with a year-to-date increase of 28.05% [1] Group 1: Index Performance - The China Securities Index for Hong Kong Stock Connect Medical Theme Index closed at 849.54 points with a trading volume of 15.301 billion yuan [1] - Over the past month, the index has increased by 6.08%, and over the last three months, it has risen by 9.80% [1] Group 2: Index Composition - The index comprises 50 listed companies involved in medical devices, medical services, pharmaceuticals, and biotechnology [1] - The top ten weighted companies in the index include WuXi Biologics (16.26%), JD Health (10.67%), Alibaba Health (6.31%), WuXi AppTec (5.79%), China National Pharmaceutical Group (5.31%), Kingstar BioTech (4.27%), Weigao Group (3.31%), Innovent Biologics (3.06%), CSPC Pharmaceutical Group (2.51%), and MicroPort Scientific Corporation (2.4%) [1] Group 3: Index Adjustment Mechanism - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2]

Financial Position - The group's total current assets as of March 31, 2025, amounted to RMB 368.34 billion, compared to RMB 368.03 billion as of December 31, 2024, reflecting a slight increase[6]. - Accounts receivable increased to RMB 221.77 billion from RMB 182.76 billion, indicating a growth of approximately 21.4% year-over-year[6]. - The group's cash and cash equivalents decreased to RMB 45.36 billion from RMB 67.07 billion, representing a decline of about 32.4%[6]. - Inventory levels rose to RMB 66.22 billion, up from RMB 60.94 billion, marking an increase of approximately 8.5%[6]. - Non-current assets totaled RMB 46.74 billion, slightly up from RMB 46.64 billion, showing a marginal growth[6]. - The total assets of the group reached RMB 415.08 billion, compared to RMB 392.67 billion in the previous period, reflecting an increase of approximately 5.7%[6]. - Total liabilities as of March 31, 2025, amounted to RMB 285.93 billion, an increase of 7.83% from RMB 265.76 billion as of December 31, 2024[7]. - Current liabilities totaled RMB 274.03 billion, up from RMB 250.31 billion, indicating a significant increase in short-term financial obligations[7]. - Non-current liabilities decreased to RMB 11.90 billion from RMB 15.45 billion, suggesting a reduction in long-term debt commitments[7]. - The company's total equity reached RMB 129.16 billion, an increase from RMB 126.91 billion, reflecting a positive trend in shareholder equity[7]. Revenue and Profitability - Total operating revenue for the three months ended March 31, 2025, was RMB 141.66 billion, a decrease of 3.67% from RMB 147.27 billion for the same period in 2024[8]. - Net profit for the three months ended March 31, 2025, was RMB 2.26 billion, compared to RMB 2.40 billion in the previous year, indicating a decline of 5.83%[9]. - The company reported a basic and diluted earnings per share of RMB 0.47 for the three months ended March 31, 2025, compared to RMB 0.46 for the same period in 2024[9]. - Total operating costs for the same period were RMB 138.05 billion, down from RMB 143.49 billion, reflecting a cost reduction strategy[8]. - The total operating revenue for the three months ended March 31, 2025, was RMB 5,213,357,504.88, an increase of 6.1% compared to RMB 4,912,928,587.87 for the same period in 2024[18]. - Net profit for the same period was RMB 271,526,239.09, significantly up from RMB 48,414,009.21 in 2024, representing a growth of 461.5%[18]. - Operating profit increased to RMB 281,267,703.10 from RMB 49,745,649.99, marking a rise of 465.5% year-over-year[18]. - The total operating costs for the period were RMB 5,153,579,593.46, an increase from RMB 4,904,594,485.93 in 2024[18]. Cash Flow - Operating cash flow for the three months ended March 31, 2025, was a net outflow of RMB 34.28 billion, an improvement from a net outflow of RMB 47.48 billion for the same period in 2024, representing a 27.5% reduction in cash outflow[10]. - Cash flow from operating activities showed a net outflow of RMB 2,259,793,996.48, compared to a net outflow of RMB 1,912,528,692.92 in the previous year[21]. - Cash flow from investing activities generated a net inflow of RMB 969,545,995.42, up from RMB 407,324,780.59 in 2024[21]. - Cash inflow from financing activities for the three months ended March 31, 2025, was RMB 32.59 billion, a decrease of 20.9% from RMB 41.22 billion in 2024[11]. - The company's net cash flow from financing activities was RMB 12.88 billion for the three months ended March 31, 2025, down 41.5% from RMB 22.15 billion in 2024[11]. - Cash flow from financing activities resulted in a net outflow of RMB 14,237,506,923.58, compared to RMB 17,134,426,936.48 in the previous year[22]. Investments and Strategic Focus - The group has ongoing investments in fixed assets, with a total of RMB 10.52 billion as of March 31, 2025[6]. - The group continues to focus on expanding its market presence and enhancing its product offerings through strategic investments and partnerships[6]. - The company reported a significant increase in investment income, reaching RMB 230,253,895.71, compared to RMB 53,504,018.73 in the same period last year[18]. - The company reported an investment income of RMB 222.21 million, up from RMB 150.12 million, highlighting improved performance in investment activities[8]. - Research and development expenses for the three months were RMB 63.26 million, down from RMB 71.13 million, indicating a potential shift in investment strategy[8]. Inventory and Asset Management - The group reported a significant increase in prepayments, which rose to RMB 7.86 billion from RMB 6.80 billion, indicating a growth of about 15.6%[6]. - The group's goodwill remained stable at approximately RMB 6.20 billion, showing minimal change from the previous period[6]. - The company reported a total inventory of RMB 1.25 billion as of March 31, 2025, up from RMB 1.05 billion at the end of 2024, indicating a 19.3% increase[12]. - The company's long-term borrowings decreased to RMB 1.49 billion as of March 31, 2025, from RMB 4.65 billion at the end of 2024, a significant reduction of 68.0%[15]. - Current liabilities decreased to RMB 43.30 billion as of March 31, 2025, from RMB 55.42 billion at the end of 2024, a reduction of 21.9%[15]. - The total equity increased to RMB 33.57 billion as of March 31, 2025, compared to RMB 33.29 billion at the end of 2024, showing a growth of 0.8%[16]. - Cash and cash equivalents decreased to RMB 33.53 billion as of March 31, 2025, from RMB 38.74 billion at the end of 2024, a decline of 13.4%[11]. - The cash and cash equivalents at the end of the period stood at RMB 14,672,100,199.21, compared to RMB 14,194,374,852.87 at the end of March 2024[22].

Company Overview - Sinopharm Group Co. Ltd. is a leading wholesaler and retailer of pharmaceuticals and medical devices in China, with a strong distribution network covering the entire country[3]. - The company has established a leading position in the Chinese pharmaceutical retail industry through direct management and franchising of retail pharmacy networks[4]. - Sinopharm Group aims to leverage its scale advantages and customer resources to further consolidate and enhance its market leadership in the pharmaceutical and healthcare industry[4]. - The company is actively innovating and exploring diversified business development in the pharmaceutical and healthcare sectors[4]. - Sinopharm Group's vision is to become an excellent global provider of pharmaceutical health services, focusing on technology and innovation[5]. - The company is committed to providing comprehensive distribution, delivery, and value-added services to manufacturers and suppliers of pharmaceuticals and medical products[4]. - Sinopharm Group is positioned to capitalize on the stable growth of the pharmaceutical and healthcare market in China, aligning with industry policies and seizing development opportunities[4]. - The company has a robust governance structure with a diverse board of directors and various committees overseeing strategic and operational decisions[7]. - Sinopharm Group's headquarters is located in Shanghai, China, with a significant operational presence in Hong Kong[9]. - The company is focused on continuous improvement and aims to become an efficient organizer of pharmaceutical supply chains and a comprehensive service provider in the industry[4]. Financial Performance - Total revenue for 2023 reached RMB 596,569,565 thousand, representing a year-over-year increase of 8.0% from RMB 552,147,550 thousand in 2022[14]. - Gross profit for 2023 was RMB 48,511,678 thousand, with a gross margin of 8.13%, down from 8.59% in 2022[14]. - Operating profit for 2023 was RMB 20,209,195 thousand, reflecting a slight decrease from RMB 20,604,466 thousand in 2022, resulting in an operating profit margin of 3.39%[14]. - Net profit attributable to shareholders for 2023 was RMB 9,053,760 thousand, an increase of 6.2% compared to RMB 8,525,655 thousand in 2022[14]. - Total assets as of 2023 amounted to RMB 383,394,844 thousand, up from RMB 364,775,134 thousand in 2022[14]. - The company reported a decrease in net profit margin to 2.52% in 2023 from 2.60% in 2022, indicating pressure on profitability[14]. - In 2024, the company's total revenue reached RMB 584,507.93 million, a year-on-year decrease of 2.02%[31]. - The net profit attributable to shareholders was RMB 7,049.68 million, down 22.14% year-on-year[31]. - The pharmaceutical distribution segment's revenue share increased by 1.72 percentage points to 73.16%[32]. - The medical device distribution segment's revenue share decreased by 1.68 percentage points to 19.41%[32]. - The retail pharmaceutical segment's revenue share increased by 0.14 percentage points to 5.92%[32]. Market and Strategic Initiatives - The company aims to enhance its service capabilities and innovate service models, focusing on B2B and B2C services to drive growth[19]. - The company is actively pursuing digital transformation strategies, including the application of AI technology in supply chain management and logistics[20]. - The company is focusing on strategic transformation and innovation to adapt to regulatory challenges and industry upgrades[32]. - The company expanded its direct sales business, which showed steady growth, focusing on high-level hospitals and retail terminals, enhancing resource allocation efficiency in key regions like Jiangsu, Zhejiang, and Shanghai[34]. - The company launched 12 marketing self-operated projects in collaboration with Pfizer and Novartis, enhancing the marketing system for oncology, infections, and respiratory diseases[35]. - The company added 337 new smart supply chain projects across 30 provinces, including 110 SPD projects and 217 centralized distribution projects for single hospitals[38]. - The company is focusing on compliance-driven channel optimization and enhancing service capabilities in response to regulatory changes in the medical device sector[36]. - The company is actively pursuing innovative service development, with 15 new service-related patents and 74 software copyrights in areas like medical equipment management and supply chain management[38]. - The implementation of electronic prescriptions is accelerating the flow of prescriptions outside hospitals, benefiting specialized pharmacies with strong service capabilities[39]. - The company is adjusting its product mix towards high-demand, high-value categories, driving growth in clinical high-value products[35]. Governance and Compliance - The company has a robust governance framework to manage risks and uncertainties in its operations[178]. - The board consists of 15 members, including 2 executive directors and 5 independent non-executive directors, ensuring a diverse skill set and experience[101]. - The company maintains a high standard of corporate governance, continuously improving its governance and disclosure practices[96]. - The board has established various committees, including audit, remuneration, and strategic investment committees, to enhance corporate governance and oversight[107]. - The company emphasizes long-term sustainable development, focusing on employee value and maintaining good relationships with suppliers and customers[95]. - The company has established a risk management and internal control system to manage risks associated with achieving business objectives[143]. - Major risks for 2024 include policy risk, cash flow risk, and risks related to reform and business transformation[146]. - The company aims to enhance integrated operational capabilities and improve supply chain service capabilities in response to rapid market changes[146]. - The company has established a comprehensive risk management and internal control organizational system, including multiple defense lines[144]. - The company has mechanisms in place for independent directors to provide objective opinions, enhancing decision-making effectiveness[113]. Human Resources and Employee Relations - The total number of employees decreased from 115,959 as of December 31, 2023, to 108,217 as of December 31, 2024[86]. - The employee gender ratio among senior management is approximately 1:0.4, while the overall employee gender ratio (excluding senior management) is about 1:1.7[88]. - The group has established a standardized compensation management system based on performance, with a focus on efficiency and fairness[87]. - The company is committed to creating a harmonious work environment and competitive compensation for employees, ensuring a strong human resource advantage for future development[95]. - The company prioritizes talent development, technological innovation, and compliance culture to strengthen its operational management and environmental safety[97]. Future Outlook and Strategic Goals - The company aims to become an excellent global provider of pharmaceutical health services, aligning with the "Healthy China" strategy to meet the growing needs of the population[99]. - The company is committed to developing new products and technologies to meet evolving market demands and improve patient outcomes[158]. - Future strategies include potential mergers and acquisitions to enhance market share and product offerings[158]. - The company is focusing on developing value-added services such as pre-listing services, import agency, market access, and retail channel services to find new profit growth points[147]. - The company is accelerating its digital transformation and applying AI technology to improve business efficiency and customer experience[147].

Core Viewpoint - The company, China National Pharmaceutical Group (Sinopharm), reported its first decline in both revenue and net profit since its listing in Hong Kong 15 years ago, with a significant drop in net profit exceeding 20% in 2024 due to a slowdown in its high-margin medical device distribution business [1] Financial Performance - In 2024, the total revenue was approximately 458.45 billion, a decrease from 596.57 billion in 2023, marking a decline of about 2.5% [2] - The gross profit for 2024 was 44.26 billion, down from 48.51 billion in 2023, indicating a decrease of approximately 8.5% [2] - The operating profit fell to 16.19 billion from 20.21 billion, a decline of about 20% [2] - The net profit attributable to the parent company was 7.05 billion, down from 9.05 billion, reflecting a decrease of approximately 22% [3] Business Segment Analysis - The pharmaceutical distribution segment generated revenue of approximately 444.37 billion, accounting for about 73.16% of total revenue, with growth driven by an increase in procurement variety [3] - The medical device distribution segment saw revenue of approximately 117.91 billion, a year-on-year decline of 9.44%, primarily due to changes in end-user demand and a decrease in sales of high-margin device categories [3] - The retail segment achieved revenue of 35.98 billion, a slight increase of 0.82%, but the operating profit margin decreased by 2.31 percentage points to 0.90% [4] Subsidiary Performance - Sinopharm's subsidiary, Sinopharm Holding GuoDa Drugstores, experienced a revenue decline of about 8%, while its net profit dropped by 110.36% [4] - Sinopharm's other subsidiary, Sinopharm Weiye, reported a revenue decrease of 7.75% and a net profit decline of 60.88%, with a significant drop in cash flow from operating activities by 285.26% [5]

Economic Performance - In 2024, China's GDP grew by 5%, indicating economic resilience despite challenges in domestic demand[5]. - The total income of the national basic medical insurance fund in 2024 is RMB 3.48 trillion, a year-on-year increase of 4.4%[70]. - The total expenditure of the national basic medical insurance fund in 2024 is RMB 2.97 trillion, a year-on-year increase of 5.5%[70]. - The company anticipates continued growth in the pharmaceutical and healthcare industry driven by increasing demand for medical services due to an aging population[70]. Financial Performance - Total revenue for 2024 was RMB 584,507,930, a decrease of 2% from RMB 596,569,565 in 2023[13]. - Gross profit for 2024 was RMB 44,255,390, down 9% from RMB 48,511,678 in 2023[13]. - Operating profit decreased to RMB 16,188,403 in 2024, down 20% from RMB 20,209,195 in 2023[13]. - Net profit for the year was RMB 10,423,594, a decline of 30% compared to RMB 15,009,828 in 2023[15]. - Basic and diluted earnings per share for 2024 were RMB 2.26, down from RMB 2.90 in 2023[15]. - The company reported a decrease in other comprehensive income, totaling RMB 10,380,586 in 2024 compared to RMB 15,008,975 in 2023[17]. - The expected credit loss for financial and contract assets in 2024 was RMB 1,381,347 thousand, up from RMB 666,966 thousand in 2023, showing a significant increase of 106.8%[36]. - Other income, net, decreased significantly to RMB 46,923 thousand in 2024 from RMB 661,284 thousand in 2023, a decline of 92.9%[43]. - The impairment charge for intangible assets was RMB 1,105,964 thousand in 2024, compared to RMB 51,098 thousand in 2023, indicating a substantial increase in impairment losses[44]. - The total proposed final dividend for the year ending December 31, 2024, is RMB 0.68 per share, down from RMB 0.87 per share in 2023, which totals approximately RMB 2,122,046 thousand[67]. Assets and Liabilities - Total assets increased to RMB 392,831,244 in 2024, compared to RMB 383,394,844 in 2023, reflecting a growth of 2%[19]. - Total liabilities rose to RMB 266,143,942 in 2024, up from RMB 263,076,099 in 2023[20]. - Cash and cash equivalents decreased to RMB 54,313,359 in 2024 from RMB 63,808,538 in 2023, a decline of 15%[19]. - Trade receivables increased to RMB 187,635,430 thousand in 2024 from RMB 169,002,890 thousand in 2023, representing an increase of approximately 11%[56]. - The company's trade payables increased to RMB 112,450,243 thousand in 2024 from RMB 108,952,818 thousand in 2023, reflecting an increase of about 3%[64]. - The group's debt-to-asset ratio was 67.75% as of December 31, 2024, compared to 68.62% as of December 31, 2023[137]. Business Strategy and Operations - The pharmaceutical industry faces challenges such as regulatory changes and a shift from resource-driven expansion to quality and efficiency-focused competition[6]. - The company is enhancing its service capabilities, focusing on B2B and B2C services, and developing a "second growth curve" through marketing, logistics, and private label manufacturing[6]. - The company is advancing its digital transformation strategy, aiming for full-process visibility in logistics and efficient resource allocation through technology[7]. - The company plans to strengthen its strategic leadership and improve business control capabilities while exploring innovative capital operation methods[12]. - The company aims to enhance operational efficiency and compliance through integrated management across procurement, logistics, and finance[9]. - The company is committed to responding to public health emergencies and ensuring rapid supply during critical events[10]. - The company is focusing on high-quality development and transformation as a core business goal, with a strategic emphasis on the upcoming "15th Five-Year Plan"[12]. - The company is determined to lead the pharmaceutical distribution industry's development and transformation amid ongoing macroeconomic trends[12]. - The group recognizes four main business segments: pharmaceutical distribution, medical device distribution, pharmaceutical retail, and other businesses, with pharmaceutical retail identified as a potential growth area[33]. - The group plans to deepen digital transformation to enhance overall organizational control and operational efficiency[101]. Compliance and Governance - The group has adopted new and revised Hong Kong Financial Reporting Standards effective from January 1, 2024, including HKFRS 16 (revised) related to sale and leaseback transactions[27]. - The group reported that the application of the revised HKAS 7 and HKFRS 7 clarifies the characteristics of supplier financing arrangements, requiring additional disclosures to help users understand the impact on liabilities and cash flow risks[27]. - The group has not early adopted the newly issued and revised HKFRS that may potentially impact its consolidated financial statements, indicating a cautious approach to regulatory changes[28]. - The group’s financial statements are prepared based on historical cost, except for certain financial assets measured at fair value[25]. - The company has adopted all provisions of the Corporate Governance Code as its corporate governance guidelines and has complied with these provisions during the reporting period[166]. - The board has adopted the Standard Code as the rules governing the trading of the company's listed securities by directors and supervisors, confirming compliance during the reporting period[168]. Market and Competitive Landscape - The company is focusing on compliance, digitalization, and professionalization as core competitive advantages for future growth[75]. - The company is actively optimizing its distribution network and adjusting strategies based on regional market differences to enhance market share[80]. - The pharmaceutical distribution segment generated revenue of RMB 444,364,612 thousand in 2024, slightly up from RMB 441,050,702 thousand in 2023, indicating a growth of 0.7%[36]. - The medical device distribution segment recorded revenue of RMB 117,915.14 million, a year-on-year decrease of 9.44%, with an operating profit margin of 2.25%, down 1.23 percentage points from the previous year[83]. - The pharmaceutical retail segment achieved revenue of RMB 35,981.26 million, a year-on-year increase of 0.82%, with an operating profit margin of 0.90%, down 2.31 percentage points from the previous year[89]. - The group expanded its smart supply chain projects to 30 provinces, adding 337 projects, including 110 SPD projects and 217 centralized distribution projects for single hospitals[86].